RUSH UNIVERSITY MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $87.3M
- Transactions
- 9,748
- Companies
- 40
- Average per transaction
- $8,958
Who reported the payments
| Merck | $6,663,731 |
| Genentech, Inc. | $6,491,172 |
| AstraZeneca | $3,565,940 |
| AbbVie | $3,317,017 |
| Abbott | $3,160,552 |
| Novartis | $3,050,138 |
| Amgen | $2,875,547 |
| United Therapeutics Corporation | $2,725,375 |
| Ultragenyx Pharmaceutical Inc. | $2,288,483 |
| Astrazeneca UK Limited | $2,187,351 |
| Pfizer | $1,813,911 |
| Gilead | $1,688,730 |
| Bristol Myers Squibb | $1,661,360 |
| Biogen | $1,615,403 |
| Sobi, Inc | $1,536,679 |
| Boston Scientific | $1,505,980 |
| Sanofi | $1,433,558 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,384,560 |
| Medtronic | $1,305,255 |
| Janssen Scientific Affairs, LLC | $1,210,399 |
| Janssen Research & Development, LLC | $1,127,696 |
| Edwards Lifesciences | $1,118,408 |
| Regeneron | $1,087,943 |
| Zimmer Biomet | $1,078,046 |
| Beigene, Ltd. | $991,981 |
| Seagen Inc. | $987,125 |
| Lilly USA, LLC | $884,125 |
| Incyte Corporation | $857,873 |
| E.r. Squibb & Sons, L.L.C. | $856,804 |
| Stryker | $852,165 |
| Mallinckrodt Hospital Products Inc. | $800,792 |
| Exelixis Inc. | $752,131 |
| Eisai Inc. | $706,530 |
| Mallinckrodt Enterprises LLC | $653,470 |
| Sage Therapeutics, LLC | $642,284 |
| Roche Products Limited | $610,103 |
| Boehringer Ingelheim | $588,149 |
| Angiodynamics, Inc. | $562,607 |
| KARL Storz Endoscopy-america | $556,655 |
| Sanofi US Services Inc. | $553,397 |